Related Experiment Video
Updated: Apr 16, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Dual antiplatelet therapy for coronary artery disease
1Division of Cardiology, Heart Institute, Asan Medical Center, University of Ulsan, Seoul, Korea.
Insights
Dual antiplatelet therapy (DAPT) reduces stent thrombosis after coronary stent placement. Guidelines recommend DAPT for 6-12 months after drug-eluting stents and 12 months after acute coronary syndrome, balancing benefits against bleeding risks.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Platelets are crucial in thrombus formation at arterial injury sites.
- Dual antiplatelet therapy (DAPT) with aspirin and ticlopidine is standard for preventing stent thrombosis.
- Clopidogrel and newer P2Y12 inhibitors offer alternatives with improved safety profiles.
Purpose of the Study:
- To review current guidelines and evidence for DAPT duration after coronary stent implantation.
- To compare the efficacy and safety of different antiplatelet regimens.
- To highlight the balance between preventing ischemic events and managing bleeding risk.
Main Methods:
- Review of current clinical guidelines and landmark clinical trials.
- Analysis of data comparing DAPT with aspirin alone and different P2Y12 inhibitors.
- Evaluation of safety outcomes, particularly major bleeding events.
Main Results:
- DAPT is superior to aspirin alone in preventing recurrent events in acute coronary syndrome (ACS).
- Newer P2Y12 receptor blockers show improved outcomes compared to clopidogrel in ACS patients.
- Extended DAPT duration (6-12 months for DES, 12 months for ACS) is recommended, but increases bleeding risk.
Conclusions:
- DAPT is essential for preventing stent thrombosis and recurrent events after ACS.
- Optimal DAPT duration requires balancing anti-ischemic benefits against increased bleeding risk.
- Current recommendations advocate for at least 6-12 months of DAPT after DES implantation and 12 months after ACS.
Abstract:
Platelets initiate the formation of a thrombus at the site of an arterial injury, and the clotting cascade is activated as the thrombus matures. After coronary stent placement, dual antiplatelet therapy (DAPT) with aspirin and ticlopidine dramatically reduces the risk of stent thrombosis, compared with anticoagulation therapy, and has become the standard of care for prevention of stent thrombosis. Clopidogrel is a second-generation thienopyridine that eliminates the serious side effects of ticlopidine, and new P2Y12 receptor blockers have emerged to overcome the limitations of clopidogrel. Current guidelines recommend DAPT with aspirin and clopidogrel for 1 month after implantation of bare-metal stents, and for 6-12 months after implantation of drug-eluting stents (DES). In patients with acute coronary syndrome (ACS), DAPT administration for 12 months was shown to be superior to aspirin alone for the prevention of recurrent events. Treatment with aspirin and new P2Y12 receptor blockers has further reduced the rate of cardiovascular death, myocardial infarction or stroke after ACS compared with aspirin and clopidogrel. Nonetheless, long-term DAPT increases the risk of major bleeding, requiring a delicate balance between anti-ischemic benefit and bleeding risk. In summary, DAPT should be maintained for at least 6-12 months after implantation of DES, and for at least 12 months after ACS, unless contraindicated.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Angina IV: Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures